The estimated Net Worth of Priti Patel is at least $143 Thousand dollars as of 31 March 2023. Dr Patel owns over 10,000 units of Neoleukin Therapeutics stock worth over $143,376 and over the last 3 years he sold NLTX stock worth over $0.
Sign up
Dr S NLTX stock SEC Form 4 insiders trading
Dr has made over 3 trades of the Neoleukin Therapeutics stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 10,000 units of NLTX stock worth $34,900 on 31 March 2023.
The largest trade he's ever made was exercising 35,000 units of Neoleukin Therapeutics stock on 1 February 2023 worth over $122,150. On average, Dr trades about 7,857 units every 48 days since 2021. As of 31 March 2023 he still owns at least 41,082 units of Neoleukin Therapeutics stock.
You can see the complete history of Dr Patel stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Priti Patel M.D., M.S. biography
Dr. Priti Patel M.D., M.S. is the Chief Medical Officer at Neoleukin Therapeutics.
What's Dr S's mailing address?
Priti's mailing address filed with the SEC is C/O NEOLEUKIN THERAPEUTICS, INC., 188 EAST BLAINE STREET, #450, SEATTLE, WA, 98102.
Insiders trading at Neoleukin Therapeutics
Over the last 5 years, insiders at Neoleukin Therapeutics have traded over $425,653 worth of Neoleukin Therapeutics stock and bought 6,490,231 units worth $38,477,971 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Group, Llc Green Jeremy Red..., and Bros. Advisors Lp667, L.P.B.... On average, Neoleukin Therapeutics executives and independent directors trade stock every 37 days with the average trade being worth of $593,084. The most recent stock trade was executed by Bros. Advisors Lp667, L.P.B... on 15 August 2023, trading 2,285,342 units of NLTX stock currently worth $1,462,619.
What does Neoleukin Therapeutics do?
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
What does Neoleukin Therapeutics's logo look like?
Complete history of Dr Patel stock trades at Neoleukin Therapeutics
Neoleukin Therapeutics executives and stock owners
Neoleukin Therapeutics executives and other stock owners filed with the SEC include:
-
Jonathan Drachman,
President, Chief Executive Officer, Director -
Dr. Jonathan G. Drachman,
CEO, Pres & Director -
Robert Ho,
Chief Financial Officer -
Todd Simpson,
Independent Chairman of the Board -
Lewis Williams,
Independent Director -
Sarah Noonberg,
Independent Director -
M. Cantey Boyd,
Independent Director -
Erin Lavelle,
Director -
Martin Babler,
Director -
Samantha Willing,
Vice President - People -
Leslie Aberman,
Vice President - Legal Affairs and Intellectual Property -
Robert Ho,
Chief Financial Officer, Secretary -
Dr. Bill Arthur,
VP & Head of Research -
Dr. Priti Patel M.D., M.S.,
Chief Medical Officer -
Umut Ulge,
VP of Clinical Devel. -
Dr. Carl Walkey Ph.D.,
Sr. VP of Corp. Devel. -
Holly K. Vance,
Gen. Counsel -
Dr. David Baker,
Co-founder & Member of Scientific Advisory Board -
Kamran Alam,
Sr. Strategic Advisor -
Group, Llc Green Jeremy Red...,
-
Sean Michael Smith,
Interim CFO, Prin Acct Off -
Holly Vance,
General Counsel -
Sean P. Nolan,
Director -
Bros. Advisors Lp Baker Bro...,
-
Priti Patel,
-
Carl Walkey,
Senior Vice President -
Bros. Advisors Lp667, L.P.B...,
-
Erin M. Lavelle,
Director -
Bros. Advisors Lp667, L.P.B...,
-
Donna Cochener,
General Counsel, SVP Legal -
Rohan Palekar,
Director